For the first time since 2013, Bristol-Myers Squibb reported a year-over-year quarterly ad spending increase. Advertising and product promotion costs rose 13% to $193 million, following two quarters of double-digit decreases this year--and a 14% overall decrease for all of 2014. The last time ad spending was up year over year was 2013's fourth quarter.
A new semimonthly treatment from Johnson & Johnson and ViiV Healthcare tamped down HIV as well as daily therapy in a midstage trial, promising a more convenient option for patients.
Nonprofit incubator Fogarty Institute for Innovation is partnering with Johnson & Johnson's surgical device specialist Ethicon to develop next generation medical devices. Ethicon will sponsor the Institute to support its educational programs as well as offer leadership and mentorship to its resident med tech innovators.
After years of setbacks, Johnson & Johnson's Yondelis finally has its shot at some U.S. sales. The drug won its sought-after FDA approval Friday--not in ovarian cancer as previously hoped, but as a treatment for soft-tissue sarcoma, which otherwise has few treatment options.
Johnson & Johnson is shaking up its med tech innovation model. Its sprawling medical device unit had a quarterly operational sales increase of just 1.3% to $6.1 billion when adjusting for divestitures and foreign currency fluctuations. Add a negative currency impact to the equation, and the growth rate was-7.3%.
Once upon a time, analysts thought the cancer-fighting prospect Yondelis could hit $1 billion in sales by 2010. But that timetable went poof years ago--and so did the forecast--as the drug failed to win the FDA's approval, and eventually ended up in a partnership between Spain's Zeltia and Johnson & Johnson's Janssen unit.
About 6 years after its first rejection, Johnson & Johnson's long-delayed cancer drug Yondelis won FDA approval to treat soft tissue sarcomas, finding success in its third go round.
Johnson & Johnson has added another company to its ever-growing network of third-party drug discovery allies. The latest deal sees J&J subsidiary Janssen Biotech follow GlaxoSmithKline, Merck, Novartis and others by hooking up with Nuevolution to get a look at its drug discovery platform.
Johnson & Johnson scored a victory in the first case to go to trial over claims that its blockbuster painkiller Tylenol causes liver damage and its dosing doesn't adequately account for the risk. A New Jersey jury ruled that the plaintiff did not prove that she took the painkiller.
Johnson & Johnson's Stelara may be under fire in psoriasis. But the New Jersey drugmaker has new data suggesting it'll be able to score elsewhere.